The GABA(B) receptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory

被引：42
|
作者：
Mondadori, C [1 ]
Mobius, HJ [1 ]
Borkowski, J [1 ]
机构：
[1] CIBA GEIGY AG,PHARMACEUT RES DEPT,CH-4002 BASEL,SWITZERLAND
来源：
BEHAVIOURAL BRAIN RESEARCH | 1996年 / 77卷 / 1-2期
关键词：
CGP; 36; 742; GABA(B); oxiracetam; memory; mouse;
D O I：
10.1016/0166-4328(95)00222-7
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
The memory-enhancing effects of a single treatment with the GABA, antagonist CGP 36 742 (10 mg/kg) or the nootropic agent oxiracetam (100 mg/kg) given immediately after a learning experience ('post-trial') remain detectable for at least 4 months thereafter. This indicates that in all probability these substances facilitate the formation of the long-term memory trace.
引用
收藏
页码：223 / 225
页数：3
相关论文
共 44 条
  • [41] Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with Satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist
    Soupart, Alain
    Gross, Peter
    Legros, Jean-Jacques
    Alfoldi, Sandor
    Annane, Djillali
    Heshmati, Hassan M.
    Decaux, Guy
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1154 - 1160
  • [42] LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats
    Kaplanski, J
    Pruneau, D
    Asa, I
    Artru, AA
    Azez, A
    Ivashkova, Y
    Rudich, Z
    Shapira, Y
    JOURNAL OF NEUROTRAUMA, 2002, 19 (08) : 953 - 964
  • [43] Tracking of long-term B-cell memory responses using B-cell receptor (BCR) sequencing in prostate cancer (PC) patients (pts) treated with sipuleucel-T (sip-T).
    Zhang, Li
    Kandadi, Harini
    Paciorek, Alan
    Chang, Nancy N.
    Sheikh, Nadeem Anwar
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [44] A phase 2, 36-week, open-label, follow-up study assessing the long-term safety and efficacy of the adenosine A2A receptor antagonist preladenant in subjects with Parkinson's disease and motor fluctuations
    Wolski, K.
    Factor, S. A.
    Togasaki, D. M.
    Huyck, S.
    Cantillon, M.
    Ho, T.
    MOVEMENT DISORDERS, 2011, 26 : S145 - S145
12345